Advertisement

Picture [iito] No Tracking 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 1037 | Ordered by Date (descending)
next pagenext page 1 2 3 4 5 6 7 8 9 10 11  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Boehringer–Vectron Biosolutions: gene expression technology, 201509– license non-excl to Vectron technology for use w BI e. coli production system 2015-09-01
Genmab–Fidelity: investment, 201509 FMR LLC increased indirect ownership to 5.9m shares = 10% of share capital + voting rights of Genmab 2015-09-01
Calibrium–Novo Group: investment, 201509 acquisition €na of Calibrium LLC by Novo Nordisk 2015-08-27
MB2–Novo Group: investment, 201509 acquisition €na of MB2 LLC by Novo Nordisk 2015-08-27
Merus–Novartis: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round incl existing investor Novartis Venture Fund 2015-08-26
Merus–SEVERAL: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round 2015-08-26
Univ Aarhus–Danaher: mass spectrometer, 201508 supply QTRAP 6500 LC-MS/MS system to Dept Clinical Biochemistry at Aarhus Univ Hospital 2015-08-26
Novartis–GSK: ofatumumab, 201508 acquisition of all rights to all indications for Arzerra for up to $1.034b by Novartis 2015-08-21
Novo Group–Genmab: bispecific antibodies, 201508– license $2m upfront use DuoBody techn by Novo Nordisk w up to $250m per license + royalties 2015-08-14
Alligator Bioscience–Investor AB: investment, 201508 existent Sunstone + Investor AB via DUBA AB are largest shareholders 2015-08-12
Alligator Bioscience–JnJ: investment, 201508 capital increase JnJ Innovation JJDC Inc acquires new shares in connection w collab for ADC-1013 2015-08-12
Alligator Bioscience–Sunstone Capital: investment, 201508 existent Sunstone + Investor AB are largest shareholders 2015-08-12
JnJ–Alligator Bioscience: antibody cancer drug, 201508–201907 TERMINATED collab + license excl ww to ADC-1013 to JBI upfront + milestones $700m + roy 2015-08-12
Alzinova–SEVERAL: investment, 201508 financing round SEK5m ($580k) 2015-08-03
Alba Therapeutics–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
BeneChill–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
BioClin Therapeutics–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
BoneSupport–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
Cerenis–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
GenSight Biologics–SEVERAL: investment, 201507 financing round Series B €36m from new + existing investors 2015-07-23
KalVista–SEVERAL: investment, 201507 financing round Series B $33m led by new investor RA Capital plus Longwood + Venrock + Novo + SV Life Sciences 2015-07-23
NephroGenex–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock 2015-07-14
Actelion–Qlucore: bioinformatics, 201507– license 3y to Omics Explorer s/w after using it since 2011 2015-07-01
Alzinova–Sweden (govt): grant, 201502– »Innovationsprojekt i företag« grant from Vinnova for Alzheimer vaccine program ALZ-101 2015-06-26
Aerocrine–Circassia: investment, 201506 acquisition of Aerocrine AB by Circassia 2015-06-18
Aerocrine–Odlander Fredrikson: investment, –201506 existent investment listed on HealthCap web site 2015-06-18
Protein Technologies (US)–Ampersand: investment, 201506 acquisition €na by Ampersand Capital Partners 2015-06-18
Biotie–SEVERAL: investment, 201506 public offering in US $56.7m (€50m) with 3.8m ADSs at $14.888/ADS Nasdaq Global Select Market 2015-06-16
Prosonix–Circassia: investment, 201506 acquisition of Prosonix Ltd by Circassia 2015-06-15
Oncos Therapeutics–Targovax: investment, 201506– merger 50/50 in shares ANNOUNCED to become Polaris 2015-06-11
Targovax–SEVERAL: investment, 201506– private placement to raise NOK125–150m + support merger w Oncos Therapeutics 2015-06-11
OmicScouts–Pelago Bioscience: drug discovery technology, 201506– license + collab developm €na CETSA method for mass spec-based proteomics 2015-06-10
Genmab–BMS: therapeutic antibodies, 201506– license excl $4m upfront + €na to panel of human antiboides targeting CD19 from BMS 2015-06-02
PRECIOUS project–CTC North: clinical research, 201506–202006 CTC North GmbH & Co KG is partner in Horizon 2020 project on stroke in elderly patients 2015-06-01
PRECIOUS project–EU (govt): grant, 201506–202006 Horizon 2020 grant €6m = total project cost co-ordinated by UMC Utrecht 2015-06-01
PRECIOUS project–Univ Hamburg: clinical research, 201506–202006 UKE is partner in Horizon 2020 project on stroke in elderly patients 2015-06-01
Biosyntia–Novo Group: investment, 201505 seed financing round totalling DKK12.5m incl lead investor Novo Seeds 2015-05-21
Biosyntia–SEVERAL: investment, 201505 seed financing round DKK12.5m led by Novo Seeds 2015-05-21
China Medical System–Faron Pharmaceuticals: Traumakine, 201505– collab developm + commercialisation in Greater China by CMS 2015-05-20
Faron Pharmaceuticals–Hume Brophy: public relations, 201505 service existent by Hume Brophy 2015-05-20
Faron Pharmaceuticals–PERSON: investment, 201505 equity investment €5m by A&B Ltd wholly-owned by Dr Lam Kong CEO of CMS 2015-05-20
Genmab–BioNTech: cancer immunotherapy, 201505– collab $10m upfront fee developm + commercialisation bispecific antibodies 2015-05-19
PsiOxus–SEVERAL: investment, 201505 financing round Series C £25m led by Imperial Innovations with Invesco + SR One + Lundbeckfond + Mercia + Woodford 2015-05-19
NeuroVive–SEVERAL: investment, 201505 private placement SEK70m directed share issue of 1.65m new shares SEK42.5/share to US investors 2015-05-08
EpiTherapeutics–Gilead: investment, 201505 acquisition by Gilead for $65m in cash 2015-05-06
Leo Pharma–Argenx: SIMPLE antibody, 201505– collab r+d + excl ww license option for ARGX-112 program for inflammatory skin disorders 2015-05-01
Newron–SEVERAL: investment, 201504 capital increase CHF24.3m private placement 843k new shares at CHF28.8/share 2015-04-30
Cytena–High-Tech Gründerfonds: investment, 201504 seed financing round totalling €1.1.m from HTGF + a private investor 2015-04-29
Cytena–SEVERAL: investment, 201504 seed financing round €1.1.m from HTGF + a private investor 2015-04-29
Univ Oslo–Medigene: DC vaccine, 201504 collab existent compassionate use in academic clinical studies in solid tumours by Oslo Univ Hospital 2015-04-20
Rigontec–SEVERAL: investment, 201503 financing round Series A 2nd closing €4.8m from Forbion Capital + Sunstone Capital 2015-03-24
Rigontec–Sunstone Capital: investment, 201503 financing round Series A 2nd closing totalling €4.8m from Forbion Capital + Sunstone Capital 2015-03-24
Nordic Nanovector–SEVERAL: investment, 201503–201504 IPO NOK500m+NOK75m at Oslo Stock Exchange at NOK32/share 2015-03-20
Univ Strasbourg–ACD/Labs: cheminformatics, 201503– supply ACD/NMR + ACD/MS Workbook Suites + ACD/Spectrus Processor 2015-03-18
Merck (DE)–Agilent: companion diagnostics, 201503 collab existent of Merck Serono + Dako 2015-03-10
BMS–Bavarian Nordic: cancer immunotherapy, 201503 acquisition excl license option to Prostvac $60m upfront + $915m milestones + tiered royalties 2015-03-04
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit 2015-03-03
Prexton Therapeutics–Merck (DE): investment, 201502 financing round Series A totalling €8.7m incl returning founding + co-investor MS Ventures 2015-02-24
Prexton Therapeutics–SEVERAL: investment, 201502 financing round Series A €8.7m co-led by Sunstone Capital + Ysios Capital plus MS Ventures 2015-02-24
Prexton Therapeutics–Sunstone Capital: investment, 201502 financing round Series A totalling €8.7m incl co-lead investor Sunstone Capital 2015-02-24
Prexton Therapeutics–Ysios Capital: investment, 201502 financing round Series A totalling €8.7m incl co-lead investor Ysios Capital 2015-02-24
NeuroVive–Baulos Capital: investment, 201502 existent Baulos Capital Belgium SA is one of largest shareholders of NeuroVive 2015-02-20
NeuroVive–SEVERAL: investment, 201502 private placement SEK65m directed share issue of 1.3m new shares 2015-02-20
Immune Targeting Systems–Vaxin: investment, 201502 acquisition merger in shares 2015-02-17
JnJ–Valneva: investment, 201502 acquisition €45m of Crucell Sweden AB + affiliates incl all assets related to Dukoral 2015-02-10
Nanion–Ratos: patch clamp technology, 201502– license non-excl to key patent providing freedom-to-operate for life time of patent from Biolin 2015-02-05
SciLifeLab (SE)–Fluidigm: CyTOF mass cytometer, 201502 supply three CyTOF 2 systems to Swedish National Center for Single-Cell Analysis 2015-02-05
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m 2015-02-01
Nanocomp–Evonik: investment, 201501– strategic minority investment €na by Evonik Venture Capital 2015-01-29
Ratos–Xention: patch clamp technology, 201501 acquisition key patent by Biolin Scientifc from Xention Ltd 2015-01-27
Cortendo–SEVERAL: investment, 201501 private placement $27.5m (SEK221m) incl RA Capital + NEA + Broadfin Capital + HealthCap 2015-01-13
Agilent–Cell Signaling Technology: diagnostic antibodies, 201501– supply €na strategic partnership to supply ABs for Dako companion Dx products 2015-01-12
Valneva–SEVERAL: investment, 201501–201502 capital increase €45m 18.23m new ordinary shares to finance acquisition of Crucell Sweden AB 2015-01-12
Genkyotex–SEVERAL: investment, 201501 financing round Series D CHF20m=$21m led by new investor NeoMed Management 2015-01-07
Baxalta–Symphogen: cancer immunotherapy, 201601– collab strategic ww €160m upfront + €1.4b milestones + roaylties in immuno-oncology 2015-01-04
Corvidia Therapeutics–Sofinnova: investment, 2015 seed financing from Sofinnova Partners 2015-01-01
Active Biotech–SEVERAL: investment, 201412 rights issue SEK225m with 15m new shares issued 2014-12-29
BerGenBio–FTI Consulting: public relations, 201412 service existent by FTI Consulting 2014-12-15
BerGenBio–SEVERAL: investment, 201412 financing round NOK90m=$15m private placing to new + existing investors 2014-12-15
Zealand Pharma–Athyrium Capital: credit, 201412– royalty bond financing $50m/DKK300m at 9.375% based on future Lyxumia (lixisenatide) revenues 2014-12-12
Symphogen–Selexis: cell line development, 201412– license to SUREtechnology platform + SURE CHO-M Cell Line + collab RnD 2014-12-09
Bayer–Orion Corp: cancer drug, 201412 existent collab ww developm + marketing of oral androgen receptor modulator ODM-201 for prostate cancer 2014-12-02
Ascendis Pharma–SEVERAL: investment, 201412 financing round Series D $60m co-led by Sofinnova Ventures + orbiMed + Vivo Capital 2014-12-01
Monocl Strategy Services–Sweden (govt): grant, 201411 Vinnova grant SEK2.7m to support launch of Moncol EGO analytics tool 2014-11-25
Perten Instruments–PerkinElmer: investment, 201411–201412 acquisition for $266m net by PerkinElmer 2014-11-24
Stratified Medical–Lundbeck: investment, before 201411 investment of DKK19m by Lundbeck 2014-11-24
Ziarco–SEVERAL: investment, 201411 financing round Series B $33.1m co-led by NEA + Lundbeckfond Ventures w Amgen + BVF + Pfizer Venture 2014-11-10
Siemens–SEVERAL: investment, 201411 acquisition of Siemens Audiology Solutions for €2.15b plus earn-out by EQT + Strüngmann family 2014-11-06
Contera Pharma–Bukwang: investment, 201411 acquisition of Contera Pharma ApS by Bukwang Pharmaceutical 2014-11-01
Bavarian Nordic–JnJ: investment, 201410– acquisition of up to 1.67m new shares for DKK251m ($43m) by J&JDC representing up to 6.4% shareholding 2014-10-22
JnJ–Bavarian Nordic: vaccine, 201410– license + supply agreem up to $144.3m for MVA-BN Filovirus vaccine with Crucell Holland BV 2014-10-22
Rigontec–SEVERAL: investment, 201410 financing round Series A 1st closing €9.45m co-led by Wellington Partners + BIVF 2014-10-14
Nexstim–SEVERAL: investment, 201410–201411 IPO €15.3m with 2.4m shares at €6,35/share at First North 2014-10-13
Nanovi–SEVERAL: investment, 201409 invesment €2.7m from current investors 2014-09-29
RSPR Pharma–SEVERAL: investment, 201409 financing round Series B €9.6m led by Novo Seeds + Sunstone Capital 2014-09-16
OnCore BioPharma–NeuroVive: cyclophilin inhibitor, 201409– license ww excl to NVP018 $150m combined upfront + milestones plus royalties 2014-09-09
Nordic Nanovector–SEVERAL: investment, 201408–201409 capital increase NOK50m (($7.8m) with 2m new shares at NOK25/share 2014-08-28
Revent Medical–Holta Invest: investment, 201406 investment by Holta Life Sciences 2014-08-06
Weifa–Holta Invest: investment, 201408 investment by Holta Life Sciences 2014-08-06
next pagenext page 1 2 3 4 5 6 7 8 9 10 11  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top